Med

Med is a flagship clinical and translational medicine journal published by Cell Press, launched in August 2020, with a 2025 Journal Impact Factor of 13.3（Med）是（Cell Press）旗下的旗舰临床与转化医学期刊，2020 年 8 月创刊，2025 年影响因子为 13.3。

Scope

• It publishes transformative science across the clinical and translational research continuum, from clinical trials to translational studies with demonstrable functional impact发表贯穿临床与转化研究全链条的变革性成果，从临床试验到具有明确功能影响的转化研究。
• The journal aims to bridge the bench-to-bedside gap by bringing cutting-edge medical thinking to clinical practice旨在弥合从实验台到床旁的鸿沟，把前沿医学思想融入临床实践。
• Topics include aging and health-span interventions such as sarcopenia, senescence and senolytic treatments, dietary interventions and hormonal disorders选题包括衰老与健康寿命干预，如肌少症、细胞衰老与衰老细胞清除疗法、饮食干预及激素紊乱。
• It covers cancer research including immuno-oncology, tumor evolution and cancer genetics, surgery and therapeutic modalities涵盖癌症研究，包括免疫肿瘤学、肿瘤演化与癌症遗传学、外科与各类治疗手段。
• It covers cardiovascular and metabolic disease such as heart disease, diabetes, obesity and NAFLD/NASH涵盖心血管与代谢疾病，如心脏病、糖尿病、肥胖与（NAFLD/NASH）。
• Biomedical engineering topics include new device optimization and diagnostic tools生物医学工程选题包括新型器械优化与诊断工具。^[1]
• The research section covers clinical case reports, first-in-human studies, large-scale clinical trials and population-based studies, and it also publishes reviews and perspectives on major health issues研究栏目涵盖临床病例报告、首次人体研究、大规模临床试验与人群研究，并发表针对重大健康问题的综述与观点文章。^[2]

History

• It was established in 2020, with its first issue released in August of that year该刊创刊于 2020 年，首期于当年 8 月出版。
• It is published by Cell Press, the imprint of Elsevier based in Cambridge, Massachusetts由（Elsevier）位于马萨诸塞州剑桥市的品牌（Cell Press）出版。
• Its founding Editor-in-Chief is Nikla Emambokus, who had previously led Cell Metabolism for a decade创刊主编为（Nikla Emambokus），她此前执掌（Cell Metabolism）十年。
• Its Journal Impact Factor reached 11.8 in 2024 and 13.3 in 2025其影响因子 2024 年为 11.8，2025 年为 13.3。
• It ranks 14th among 191 journals in the Medicine, Research and Experimental category of the 2025 Journal Citation Reports and is in the Q1 quartile在 2025 年期刊引证报告中位列（MEDICINE, RESEARCH & EXPERIMENTAL）类别 191 种期刊第 14 位，属 Q1 区。
• It offers subscription and open access publication options, the latter with an article publishing charge of 9,350 US dollars该刊提供订阅与开放获取两种出版选项，后者收取 9,350 美元版面费。

Editors

• Nikla Emambokus is the Editor-in-Chief of the journal（Nikla Emambokus）担任该刊主编。
• She holds a doctorate in biochemistry and molecular biology from the University of Oxford她拥有（University of Oxford）生物化学与分子生物学博士学位。
• She conducted postdoctoral research at the Weatherall Institute of Molecular Medicine and at Boston Children's Hospital with Harvard Medical School她先后在（Weatherall Institute of Molecular Medicine）以及（Boston Children's Hospital）与（Harvard Medical School）从事博士后研究。
• The scientific editors include Swapnika Ramu, who earned her doctorate at the University of Southern California科学编辑包括（Swapnika Ramu），她在（University of Southern California）获得博士学位。
• Jiani Xiao, a graduate of Shanghai Jiao Tong University School of Medicine, also serves as a scientific editor（Jiani Xiao）毕业于（Shanghai Jiao Tong University School of Medicine），同样担任科学编辑。
• Other scientific editors include Duc Le, Mari-Carmen Fernandez-Aguera and Vanessa Beijamini其他科学编辑还包括（Duc Le）、（Mari-Carmen Fernandez-Aguera）与（Vanessa Beijamini）。